Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on May 5, 2021. The registrant is a Delaware corporation headquartered in South San Francisco, California, with common stock trading on Nasdaq under the symbol CBIO.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material event reported is the commencement of a pivotal clinical trial:
- Event: Dosing of the first patient in the Crimson 1 Study.
- Study Type: Phase 3 registration trial (MAA-304 - Crimson 1).
- Product: Marzeptacog alfa (activated), also known as MarzAA.
- Indication: Treatment for individuals with Hemophilia A or B with inhibitors.
- Administration: Subcutaneously (SQ) administered next-generation engineered recombinant coagulation Factor VIIa (rFVIIa).
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the study initiation. No specific financial guidance, quantitative outlook, or new risk factors were disclosed in the text of this 8-K. The filing explicitly states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability.
Investor Verification Checklist
- Verify the full details of the Crimson 1 Study protocol and enrollment targets in the attached press release (Exhibit 99.1).
- Confirm the regulatory status of MarzAA and the timeline for potential Marketing Authorization Application (MAA) submission.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor subsequent filings for patient enrollment milestones and interim data readouts from the Phase 3 trial.